DynaMed, LLC

Better growth leads to generally better outcomes in neonates.

They went away and they searched Medline, Embase, Sinal, and Dynamed in order to come up with some answers.

They found 42 potential articles, seven of which were relevant, a few RCTs and the rest of them being based more around retrospective cohorty sort of things.

The three main RCTs had not unreasonable numbers.

So I expect things to work the same way in medicine, and they don't unless you use Aevo.

And so we sit inside of the EHR as an intelligence layer that can take in all the patient data, run it through clinical decision support, and we currently partner with DynaMed to be able to run these questions, get concrete answers, and use that as your next step of the workflow.

And for me, the next step of my workflow is producing a note that incorporates this decision process.

And what we're able to do is in writing this note, there's also the idea of capturing what I'm doing and the complexity of the patient in that note-writing.

Every third patient asked you, "Should I get tested for lipoprotein(a)" or "How about that other one?" Where do you begin? Hi, this is Frank Domino.

And to discuss the controversial new American College of Cardiology, American Heart Association lipid guidelines is Dr. Alan Ehrlich, associate professor in the Department of Family Medicine and Community Health at the UMass Chan Medical School and executive editor of DynaMed.

Hi, Alan.

Hi, Frank.